Skip to content

TO STUDY THE EFECT OF SWAYAMBHU GUGGULU AND VISWAMITRA KAPALA TAILA IN TREATING KITIBHA KUSTHA (PLAQUE PSORIASIS)

EFFICACY OF SWAYAMBHU GUGGULU AND VISWAMITRA KAPALA TAILA IN THE MANAGEMENT OF KITIBHA KUSTHA (PLAQUE PSORIASIS) - A RANDOMIZED CONTROLLED CLINICAL TRIAL - NIL

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/05/087586
Enrollment
84
Registered
2025-05-26
Start date
Unknown
Completion date
Unknown
Last updated
2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L400- Psoriasis vulgaris

Interventions

None listed

Sponsors

Dr Pooja Sharada Jagadeesh Shanbough
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients of either sex between the age group of 18 to 70 years. 2.Patients fulfilling the diagnostic parameters of Kitibha Kustha (Plaque Psoriasis).

Exclusion criteria

Exclusion criteria: 1.Others sub varieties of Kustha. 2.Psoriasis complicated with secondary infection. 3.Lupus erythematosus. 4.Lichen Planus. 5.Pityriasis rosea. 6.Seborrhic dermatitis. 7.Pregnant and lactating women. 8.Subjects with uncontrolled metabolic diseases such as diabetes/ hypertension, hyper or hypothyroidism. 9.At the time of enrolment, if the patient is found to be non-inclusive due to any underlying health condition or medication and thus not suitable for undergoing procedures or medications will be excluded. 10.Patients with any known major anomalies like cardiac ailments, neurological ailments or congenital diseases etc. will be excluded. 11.Any medication/ therapy for Psoriasis for last one month.

Design outcomes

Primary

MeasureTime frame
It is expected that trial drug may exert a significant difference on the PASI score in the management of Kitibha Kustha (Plaque psoriasis).Timepoint: At Baseline, 7th, 14th, 21st and 30th

Secondary

MeasureTime frame
It may contribute in reducing disability adjusted life year (DALY) using PDI. It may enhance quality of life (DQLI). Timepoint: At Baseline, 7th, 14th, 21st and 30th

Countries

India

Contacts

Public ContactDr SUHAS KUMAR SHETTY

KAHERs Shri. BMK Ayurveda Mahavidyalaya

drsuhasshetty@gmail.com9449603234

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026